TapImmune Sponsors 26.2 With DONNA Marathon for Breast Cancer Research and Care
February 10, 2016
Events & Marathon to take place in Jacksonville, Florida on February 12-14, 2016
JACKSONVILLE, FLORIDA, February 10, 2016 / TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, today announced the Company is a proud sponsor of 26.2 with DONNA, a non-profit organization dedicated to funding groundbreaking breast cancer research and providing assistance to women and men who have been diagnosed with breast cancer. 26.2 with DONNA produces the only marathon in the U.S. dedicated to this cause. In the October issue of Women’s Running Magazine, WR readers voted 26.2 with DONNA their single favorite charity race. In addition, CNN recently voted 26.2 with Donna the 7th best run in the nation.
Events of this marathon weekend will take place on February 12-14, 2016 in Jacksonville, Florida. TapImmune is sponsoring the Marathon Expo on February 12-13 and will co-sponsor the marathon reception on the evening of February 12. In addition to TapImmune, sponsors include Amgen, Celgene, Genentech and companies from a broad range of industries who support breast cancer research and patient care.
“We are very proud to sponsor and support the 26.2 DONNA Marathon. Funds from DONNA events have made a significant contribution to the advancement of breast cancer research at the Mayo Clinic. We believe that by bringing industry, charitable organizations and non-profits together with public funding we can greatly facilitate the common aim to cure breast cancer,” stated Dr. Glynn Wilson Chairman & CEO of TapImmune.
About 26.2 with DONNA
26.2 with DONNA is a private non-profit organization in Northeast Florida producing the only marathon in the U.S. dedicated to breast cancer research and care. Its mission is to passionately produce world class events to raise funds for ground breaking breast cancer research and women living with breast cancer. 26.2 with DONNA net proceeds go to breast cancer research, care and awareness. Since its inaugural year in 2008, 26.2 with DONNA has contributed more than $4 million towards its vision to finish breast cancer. Funds go to the Mayo Clinic for bench top breast cancer research and to The Donna Foundation to provide financial assistance to those with breast cancer.
About TapImmune Inc.
TapImmune Inc. is an immuno-oncology company specializing in the development of innovative technologies for the treatment of cancer, including metastasis, and infectious disease. The Company’s peptide or nucleic acid-based immunotherapeutics, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patients’ killer T-cells, helper T-cells and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. The Company’s technologies may be used as stand-alone medications or in combination with current treatment modalities. Please visit the Company’s website at markertherapeutics.com for details.
Forward-Looking Statement Disclaimer
This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company’s expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are “forward-looking statements”. Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company’s most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at www.sec.gov. The Company assumes no obligation to update the forward-looking statements.
Glynn Wilson, Ph.D.
Chairman & CEO